Pharmaceutical

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

The US FDA has approved BeiGene's TEVIMBRA for oesophageal squamous cell carcinoma (ESCC) after previous systemic chemotherapy.

Mar 16, 2024 - 00:00
FDA approves BeiGene’s TEVIMBRA for oesophageal cancer
The US FDA has approved BeiGene's TEVIMBRA for oesophageal squamous cell carcinoma (ESCC) after previous systemic chemotherapy.
Read the original article

Tags:

Previous Article

Noramco launches North American pharma supply chain services provider

Next Article

Q&A: Increasing awareness around digital therapeutics key to realising full pote...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Overcoming regulatory issues with investigational medicinal product labelling 

Overcoming regulatory issues with investigational medic...

Jun 19, 2023

STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials

STAT+: Icon acquires HumanFirst to boost support for di...

Feb 29, 2024

Risk adjusted net present value: What is the current va...

Nov 18, 2023